{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:44:33Z","timestamp":1789238673045,"version":"build-2803163510"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA200437"],"award-info":[{"award-number":["CA200437"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA292664"],"award-info":[{"award-number":["R01CA292664"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009501"],"award-info":[{"award-number":["T32CA009501"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01A236615"],"award-info":[{"award-number":["R01A236615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3CA290241"],"award-info":[{"award-number":["UG3CA290241"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA235667"],"award-info":[{"award-number":["R01CA235667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022933","name":"Joanne and John Dallepezze Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pharmthera.2024.108763","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:57:14Z","timestamp":1732881434000},"page":"108763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials"],"prefix":"10.1016","volume":"266","author":[{"given":"Kyohei","family":"Misawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0005","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I Trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discovery"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108763_bb0010","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cells13131075","article-title":"Evaluation of the immunomodulatory effects of radiation for chimeric antigen receptor T cell therapy in glioblastoma multiforme","volume":"13","author":"Akhavan","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bjc.2013.415","article-title":"Stromal disrupting effects of nab-paclitaxel in pancreatic cancer","volume":"109","author":"Alvarez","year":"2013","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Molecular Therapy - Oncolytics"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108763_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","article-title":"Robust antitumor responses result from local chemotherapy and CTLA-4 blockade","volume":"6","author":"Ariyan","year":"2018","journal-title":"Cancer Immunology Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108763_bb0035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nature Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108763_bb0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discovery"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108763_bb0050","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JTO.0b013e3181f8a1bd","article-title":"The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108763_bb0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108763_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41434-018-0007-x","article-title":"Driving cars to the clinic for solid tumors","volume":"25","author":"Castellarin","year":"2018","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Current Opinion in Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108763_bb0080","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"10265","key":"10.1016\/j.pharmthera.2024.108763_bb0085","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.pharmthera.2024.108763_bb0090","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.pharmthera.2024.108763_bb0095","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Advances"},{"issue":"224","key":"10.1016\/j.pharmthera.2024.108763_bb0100","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Science Translational Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108763_bb0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nature Reviews. Disease Primers"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0115","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and TGFbeta-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"Journal of Translational Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108763_bb0125","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein & Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108763_bb0135","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108763_bb0140","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108763_bb0150","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108763_bb0155","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108763_bb0160","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0165","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jtho.2021.09.009","article-title":"Tumor and tumor-associated macrophage programmed death-ligand 1 expression is associated with adjuvant chemotherapy benefit in lung adenocarcinoma","volume":"17","author":"Gross","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0180","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","article-title":"Myeloid-derived suppressor cells: a propitious road to clinic","volume":"11","author":"Grover","year":"2021","journal-title":"Cancer Discovery"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108763_bb0185","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0200","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108763_bb0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Annals of Oncology"},{"issue":"22","key":"10.1016\/j.pharmthera.2024.108763_bb0210","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1158\/0008-5472.CAN-11-1466","article-title":"Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control","volume":"71","author":"Hong","year":"2011","journal-title":"Cancer Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108763_bb0215","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-17-1365","article-title":"T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors","volume":"24","author":"Hu","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"6622","key":"10.1016\/j.pharmthera.2024.108763_bb0225","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0235","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0240","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2217\/imt.12.112","article-title":"Cancer-associated fibroblasts as targets for immunotherapy","volume":"4","author":"Kakarla","year":"2012","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Therapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108763_bb0250","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","article-title":"Cancer-associated fibroblasts in inflammation and antitumor immunity","volume":"29","author":"Kennel","year":"2023","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0255","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108763_bb0260","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annual Review of Immunology"},{"issue":"13","key":"10.1016\/j.pharmthera.2024.108763_bb0270","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108763_bb0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ymthe.2020.10.022","article-title":"Clinical perspective: treatment of aggressive B cell lymphomas with FDA-approved CAR-T cell therapies","volume":"29","author":"Leick","year":"2021","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0280","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108763_bb0285","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells","volume":"5","author":"Lu","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0290","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/imr.12586","article-title":"The renaissance of anti-neoplastic immunity from tumor cell demise","volume":"280","author":"Ma","year":"2017","journal-title":"Immunological Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Molecular Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0300","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0305","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Molecular Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0315","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108763_bb0320","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s42255-024-00976-2","article-title":"Metabolic engineering for optimized CAR-T cell therapy","volume":"6","author":"McPhedran","year":"2024","journal-title":"Nature Metabolism"},{"issue":"499","key":"10.1016\/j.pharmthera.2024.108763_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108763_bb0330","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CJI.0000000000000413","article-title":"Clinical grade manufacture of CYAD-101, a NKG2D-based, first in class, non-gene-edited allogeneic CAR T-cell therapy","volume":"45","author":"Michaux","year":"2022","journal-title":"Journal of Immunotherapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108763_bb0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune suppressive mechanisms in the tumor microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Current Opinion in Immunology"},{"issue":"399","key":"10.1016\/j.pharmthera.2024.108763_bb0345","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0350","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nature Reviews. Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108763_bb0355","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108763_bb0360","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-22-0840","article-title":"Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy","volume":"11","author":"Quach","year":"2023","journal-title":"Cancer Immunology Research"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108763_bb0365","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108763_bb0370","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodriguez-Ruiz","year":"2018","journal-title":"Trends in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0375","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0380","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarfo","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108763_bb0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nature Reviews. Immunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108763_bb0390","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0395","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108763_bb0400","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108763_bb0405","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1434464","article-title":"Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma","volume":"7","author":"Suryadevara","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0410","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108763_bb0415","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.coi.2008.05.007","article-title":"Immunogenic cancer cell death: a key-lock paradigm","volume":"20","author":"Tesniere","year":"2008","journal-title":"Current Opinion in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108763_bb0420","doi-asserted-by":"crossref","first-page":"eade2526","DOI":"10.1126\/sciadv.ade2526","article-title":"Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma","volume":"9","author":"Uslu","year":"2023","journal-title":"Science Advances"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0430","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0435","doi-asserted-by":"crossref","first-page":"1180001","DOI":"10.3389\/fimmu.2023.1180001","article-title":"Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report","volume":"14","author":"Wang","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108763_bb0440","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108763_bb0445","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0450","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-17-1766","article-title":"NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma","volume":"24","author":"Weiss","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0460","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108763_bb0465","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s43018-023-00573-4","article-title":"c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation","volume":"4","author":"Xiong","year":"2023","journal-title":"Nature Cancer"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0470","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5112","article-title":"A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer","volume":"42","author":"Zang","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108763_bb0475","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1007\/s00432-022-04248-y","article-title":"Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs","volume":"148","author":"Zhang","year":"2022","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0480","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108763_bb0485","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nature Biotechnology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108763_bb0490","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2024.108763_bb0495","doi-asserted-by":"crossref","first-page":"1247268","DOI":"10.3389\/fimmu.2023.1247268","article-title":"Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy","volume":"14","author":"Zheng","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108763_bb0500","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Experimental Hematology & Oncology"},{"issue":"328","key":"10.1016\/j.pharmthera.2024.108763_bb0505","doi-asserted-by":"crossref","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Science Translational Medicine"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:32:37Z","timestamp":1779305557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":101,"alternative-id":["S0163725824001839"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108763","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108763"}}